Vitamin D levels and patient outcome in chronic kidney disease

Kidney International

Volumn 75, Issue 1, 2009, Pages 88-95

  Ravani, Pietro ^a,b   Malberti, Fabio ^c   Tripepi, Giovanni ^d   Pecchini, Paola ^c   Cutrupi, Sebastiano ^d   Pizzini, Patrizia ^d   Mallamaci, Francesca ^d   Zoccali, Carmine ^d,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Divisione di Nefrologia e Dialisi   (Italy)

^d CNR Consiglio Nazionale delle Ricerche   (Italy)

^e BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

1,25OH vitamin D; 25OH vitamin D; Cardiovascular risk; CKD; CKD progression; Survival

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHATE; VITAMIN D;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DIALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; TIME OF DEATH; VITAMIN SUPPLEMENTATION;

CHRONIC DISEASE; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN D;

EID: 58149156441     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.501     Document Type: Article

References (37)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
2. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
3. Quesada JM, Serrano I, Borrego F et al. Calcitriol effect on natural killer cells from hemodialyzed and normal subjects. Calcif Tissue Int 1995; 56: 113-117.
4. Hubel E, Kiefer T, Weber J et al. In vivo effect of 1,25-dihydroxyvitamin D3 on phagocyte function in hemodialysis patients. Kidney Int 1991; 40: 927-933.
5. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1353-1357.
6. Kautzky-Willer A, Pacini G, Barnas U et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47: 200-206.
7. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
8. McGonigle RJ, Fowler MB, Timmis AB et al. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron 1984; 36: 94-100.
9. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
10. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
11. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
12. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357.
13. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
14. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
15. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73: 1355-1363.
16. Thadhani R. Activated vitamin D sterols in kidney disease. Lancet 2008; 371: 542-544.
17. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169.
18. Reichel H, Deibert B, Schmidt-Gayk H et al. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-169.
19. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
21. Sims RJ, Cassidy MJ, Masud T. The increasing number of older patients with renal disease. BMJ 2003; 327: 463-464.
22. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777-783.
23. Jacob AI, Sallman A, Santiz Z et al. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984; 114: 1313-1319.
24. de Boer IH, Ioannou GN, Kestenbaum B et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69-77.
25. Ritter CS, Armbrecht HJ, Slatopolsky E et al. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70: 654-659.
26. Papapoulos SE, Clemens TL, Fraher LJ et al. Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1, 25-dihydroxycholecalciferol. Lancet 1980; 2: 612-615.
27. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916.
28. Zoccali C, Testa A, Spoto B et al. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis 2006; 47: 332-341.
29. Ertürk S, Kutlay S, Keven K. Is vitamin D receptor gene polymorphism an independent predictor of mortality in hemodialysis patients? Am J Kidney Dis 2002; 39: 441-442.
30. Zehnder D, Bland R, Chana RS et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 2002; 13: 621-629.
31. Somjen D, Weisman Y, Kohen F et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-1671.
32. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008; 11: 7-12.
33. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
34. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
35. Rahman M, Brown CD, Coresh J et al. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 2004; 164: 969-976.
36. Wei LJ, Stram DO. Analysing repeated measurements with possibly missing observations by modelling marginal distributions. Stat Med 1988; 7: 139-148.
37. Klein M. Modeling strategies for assessing interaction and confounding. In: Kleinbaum DG (ed.), Logistic Regression: A Self-Learning Text. Springer-Verlag: New York, NY, 2002, pp 161-226.